Quantcast

American College of Rheumatology Presents New Findings for The Treatment of Rheumatoid Arthritis, Says Nutri-Med Logic Corp.

October 21, 2011

Expanding on this new study and in-line with another new study done by The Department of Internal Medicine, University of Miami, Florida, Nutri-Med Logic Corp says that an internal cellular pathway is becoming a primary focus of the attention for the treatment of diseases, ranging from Rheumatoid Arthritis to cancer.

Miami, FL (PRWEB) October 21, 2011

Nutri-Med Logic Corp: A new study published in Arthritis & Rheumatism, an official monthly journal of the American College of Rheumatology, which involved a large-scale protein analysis in Rheumatoid Arthritis patients, implicates a cellular mechanism for the progression of Rheumatoid Arthritis.

The Department of Internal Medicine, University of Miami Sylvester Comprehensive Cancer, Miami, FL, also published their new findings, in The Drug magazine, which employs the same cellular mechanism for the development of anti-cancer drugs.

This mechanism is the cellular oxidation/reduction (Redox) pathways. Its dysregulation is proposed to advance Rheumatoid Arthritis and its regulation is being studied for the development of anti-cancer drugs.

Until now, chronic inflammation pathways were the main contributing factor in the development and the progression of degenerative diseases and cancer. However, recently, a new contributing factor has surfaced as to the cause and, subsequently, as a target for treatment of chronic and degenerative diseases.

The regulated redox pathways are as beneficial as the regulated inflammation pathways but, when dysregulated, it is as damaging as chronic inflammation is to the body.

Clinical (acute) inflammation is an immune mechanism and destroys anything that is foreign to the body, whereas chronic inflammation destroys or damages the body more than those that are foreign to the body.

Regulated redox pathways are also an immune and signaling mechanism and like chronic inflammation, when dysregulated, destroy or damage the body. One aspect of dysregulation is the excessive Reactive Oxygen Species (ROS), which are formed through normal cellular breathing and âœgenerallyâ become excessive due to lack of cellular anti-oxidants.

According to The Department of Internal Medicine of University of Miami, the cellular redox is regulated by three systems that counteract with free radicals and ROS, or by reversing the formation of disulfides bond [a process that relates to Protein (messenger) production].

Two of the above systems are regulated by glutathione and the third by thioredoxin.

Too much of ROS causes oxidation of glutathione (a sulfur and hydrogen containing molecule) and that competes with oxidation of protein (messenger) thiols (also containing Sulfur-hydrogen).

The S-glutathionylation (formation of protein-glutathione mixed disulfides) that happens as the result of excessive ROS is a reversible process and depends on the third system: thioredoxin.

Thioredoxin is redox agent: an anti-oxidant and a pro-oxidant. It reduces if there is an oxidative state and it oxidizes if there is a reductive (reduced) state. However, too much of thioredoxin is as damaging as too little.

Both studies, implicate the imbalance of the redox state and its relationship to proteins (messenger) production, inside the cells, as it would elating to Rheumatoid Arthritis and Cancer.

Amazingly a nutrient found in many foods, and produced by the human body, possesses the same redox ability. It reduces when there is too much oxidative stress and oxidizes when there is a reductive state. It is a pro and anti-oxidant. It is soluble in fat (lipophilic) and soluble in water (hydrophilic) and thus it travels with the blood (hydrophilic) and passes the cellular membrane (lipids) due to its lipophilic ability.

It is called R-Alpha Lipoic and it was used, in its synthetic form via IV, to treat and cure a metastasized pancreatic cancer. The FDA granted a special license for the IV application of R-Alpha Lipoic to Dr. Burton Burkson, who treated and cured a metastasized pancreatic cancer and published its results in Integrative Cancer Therapies 5; 1 March 2006, 83-89.

While there are no current IV application of R-Alpha Lipoic in Rheumatoid Arthritis patients but in studies of arthritic animals, dietary Alpha Lipoic Acid supplementation has prevented synovial inflammation and collagen-induced bone destruction (Rheumatol Int. 2010 May 23; EPUB 20496068)

Additionally, while it would be very imprudent to state that nutrients could prevent the formation of cancer or stop the progression of Rheumatic Arthritis but, without a doubt, any nutrient or food that could help to moderate chronic inflammation or improve redox imbalance must be of great value.

In conclusion, Nutri-Med Logic Corp agrees with both of the above studies but adds, now, it is a known fact that not only chronic inflammation but also redox imbalance plays key and fundamental roles in progression of diseases. Accordingly, there is a great need to investigate the role of clinical diets, containing both anti-inflammatory and anti-oxidant nutrients, as concurrent co-therapies in chronic and degenerative diseases.

Nutri-Med Logic Corp (http://www.nutrimedlogic.com) is a producer of dietary supplements such as:

R-alpha Lipoic, a potent anti-oxidant nutrient. R-Alpha Lipoic is made and known by the human body;

A Concentrated and Balanced Omega-3, a potent anti-inflammatory nutrient.

Nutri-Med Logic’s products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, sources or statements, herein, have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the supplements stated above; nor equate their supplementation to prevention, treatment or cure.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2011/10/prweb8898322.htm


Source: prweb



comments powered by Disqus